Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label trial of BRCA1/ERCC1-guided neoadjuvant chemotherapy in HER2-negative primary breast cancer
2011-005843-28Phase 2Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Jan 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide, epirubicin, fluorouracil, docetaxel, cisplatin and 1 more in breast cancer (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Pathological complete response. Started Jan 2013; status: completed.
02
Drugs
cyclophosphamideepirubicinfluorouracildocetaxelcisplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-005843-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005843-28.